Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Adaptive designs for dual-agent phase I dose-escalation studies.

Harrington JA, Wheeler GM, Sweeting MJ, Mander AP, Jodrell DI.

Nat Rev Clin Oncol. 2013 May;10(5):277-88. doi: 10.1038/nrclinonc.2013.35. Epub 2013 Mar 19. Review.

PMID:
23507740
[PubMed - indexed for MEDLINE]
2.

Phase I/II adaptive design for drug combination oncology trials.

Wages NA, Conaway MR.

Stat Med. 2014 May 30;33(12):1990-2003. doi: 10.1002/sim.6097. Epub 2014 Jan 28.

PMID:
24470329
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Dose-escalation models for combination phase I trials in oncology.

Hamberg P, Ratain MJ, Lesaffre E, Verweij J.

Eur J Cancer. 2010 Nov;46(16):2870-8. doi: 10.1016/j.ejca.2010.07.002. Epub 2010 Aug 4.

PMID:
20691584
[PubMed - indexed for MEDLINE]
4.

Methodologic guidelines for the design of high-dose chemotherapy regimens.

Margolin K, Synold T, Longmate J, Doroshow JH.

Biol Blood Marrow Transplant. 2001;7(8):414-32. Review.

PMID:
11569887
[PubMed - indexed for MEDLINE]
5.

Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.

Braun TM, Alonzo TA.

Clin Trials. 2011 Jun;8(3):247-59. doi: 10.1177/1740774511404091.

PMID:
21730075
[PubMed - indexed for MEDLINE]
6.

A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.

Koopmeiners JS, Modiano J.

Clin Trials. 2014 Feb;11(1):38-48. doi: 10.1177/1740774513500589. Epub 2013 Sep 30.

PMID:
24082004
[PubMed - indexed for MEDLINE]
7.

Design issues in dose-finding Phase I trials for combinations of two agents.

Fan SK, Venook AP, Lu Y.

J Biopharm Stat. 2009;19(3):509-23. doi: 10.1080/10543400902802433.

PMID:
19384692
[PubMed - indexed for MEDLINE]
8.

Dose escalation methods in phase I cancer clinical trials.

Le Tourneau C, Lee JJ, Siu LL.

J Natl Cancer Inst. 2009 May 20;101(10):708-20. doi: 10.1093/jnci/djp079. Epub 2009 May 12. Review.

PMID:
19436029
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.

Thall PF, Cook JD, Estey EH.

J Biopharm Stat. 2006;16(5):623-38.

PMID:
17037262
[PubMed - indexed for MEDLINE]
10.

A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.

Dejardin D, Lesaffre E, Hamberg P, Verweij J.

Pharm Stat. 2014 May-Jun;13(3):196-207. doi: 10.1002/pst.1618. Epub 2014 Apr 9.

PMID:
24715683
[PubMed - indexed for MEDLINE]
11.

Statistical designs for early phases of cancer clinical trials.

Guan S.

J Biopharm Stat. 2012;22(6):1109-26. doi: 10.1080/10543406.2011.571801. Review.

PMID:
23075011
[PubMed - indexed for MEDLINE]
12.

Dose-finding design for multi-drug combinations.

Wages NA, Conaway MR, O'Quigley J.

Clin Trials. 2011 Aug;8(4):380-9. doi: 10.1177/1740774511408748. Epub 2011 Jun 7.

PMID:
21652689
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Principles of dose finding studies in cancer: a comparison of trial designs.

Jaki T, Clive S, Weir CJ.

Cancer Chemother Pharmacol. 2013 May;71(5):1107-14. doi: 10.1007/s00280-012-2059-8. Epub 2013 Jan 9. Review.

PMID:
23299793
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Dose-finding in phase I clinical trials based on toxicity probability intervals.

Ji Y, Li Y, Nebiyou Bekele B.

Clin Trials. 2007;4(3):235-44.

PMID:
17715248
[PubMed - indexed for MEDLINE]
15.

Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges.

Mandrekar SJ, Qin R, Sargent DJ.

Stat Med. 2010 May 10;29(10):1077-83. doi: 10.1002/sim.3706.

PMID:
20419760
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A comparison of two phase I trial designs.

Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM.

Stat Med. 1994 Sep 30;13(18):1799-806.

PMID:
7997713
[PubMed - indexed for MEDLINE]
17.

A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.

Xie F, Ji Y, Tremmel L.

Contemp Clin Trials. 2012 Jul;33(4):739-48. doi: 10.1016/j.cct.2012.03.001. Epub 2012 Mar 9.

PMID:
22426247
[PubMed - indexed for MEDLINE]
18.

Adaptive designs for Phase I dose-finding studies.

Zhou Y.

Fundam Clin Pharmacol. 2010 Apr;24(2):129-38. doi: 10.1111/j.1472-8206.2009.00746.x. Epub 2009 Aug 24. Review.

PMID:
19703268
[PubMed - indexed for MEDLINE]
19.

A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).

Pan H, Xie F, Liu P, Xia J, Ji Y.

Clin Trials. 2014 Feb;11(1):49-59. doi: 10.1177/1740774513500081. Epub 2013 Oct 17.

PMID:
24137041
[PubMed - indexed for MEDLINE]
20.

Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.

Chen Z, Cui Y, Owonikoko TK, Wang Z, Li Z, Luo R, Kutner M, Khuri FR, Kowalski J.

Contemp Clin Trials. 2014 Mar;37(2):322-32. doi: 10.1016/j.cct.2014.02.004. Epub 2014 Feb 12.

PMID:
24530487
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk